|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
2
|
Glucose
|
Disorder of lung
|
1560524
|
257907
|
Glucose & Disorder of lung
|
## Chronograph ##

## Basic demographioc table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
340
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
210
|
62
|
Sex
|
gender = FEMALE
|
598
|
60
|
Sex
|
gender = FEMALE
|
559
|
56
|
Sex
|
gender = FEMALE
|
540
|
54
|
|
|
gender = MALE
|
130
|
38
|
|
gender = MALE
|
402
|
40
|
|
gender = MALE
|
441
|
44
|
|
gender = MALE
|
460
|
46
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
2
|
1
|
|
(20,30]
|
3
|
0
|
|
(20,30]
|
5
|
0
|
|
(20,30]
|
6
|
1
|
|
|
(30,40]
|
8
|
2
|
|
(30,40]
|
19
|
2
|
|
(30,40]
|
13
|
1
|
|
(30,40]
|
16
|
2
|
|
|
(40,50]
|
9
|
3
|
|
(40,50]
|
44
|
4
|
|
(40,50]
|
43
|
4
|
|
(40,50]
|
27
|
3
|
|
|
(50,60]
|
18
|
5
|
|
(50,60]
|
70
|
7
|
|
(50,60]
|
58
|
6
|
|
(50,60]
|
54
|
5
|
|
|
(60,70]
|
72
|
21
|
|
(60,70]
|
219
|
22
|
|
(60,70]
|
224
|
22
|
|
(60,70]
|
244
|
24
|
|
|
(70,80]
|
111
|
33
|
|
(70,80]
|
331
|
33
|
|
(70,80]
|
350
|
35
|
|
(70,80]
|
359
|
36
|
|
|
(80,90]
|
94
|
28
|
|
(80,90]
|
242
|
24
|
|
(80,90]
|
252
|
25
|
|
(80,90]
|
237
|
24
|
|
|
(90,110]
|
26
|
8
|
|
(90,110]
|
72
|
7
|
|
(90,110]
|
55
|
6
|
|
(90,110]
|
57
|
6
|
|
|
Median
|
77
|
IQR=(69, 84)
|
|
Median
|
74
|
IQR=(68, 83)
|
|
Median
|
74
|
IQR=(68, 82)
|
|
Median
|
74
|
IQR=(68, 82)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 340)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 340)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
4.1
|
2.1
|
-0.12
|
|
25 - 29
|
0.6
|
0.3
|
-0.04
|
Visual system disorder
|
52.4
|
35.9
|
-0.34
|
|
30 - 34
|
0.6
|
0.4
|
-0.03
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.5
|
1.4
|
-0.01
|
Atrial fibrillation
|
44.4
|
30.1
|
-0.30
|
|
40 - 44
|
0.9
|
1.5
|
0.06
|
Cerebrovascular disease
|
17.4
|
10.8
|
-0.19
|
|
45 - 49
|
1.8
|
2.6
|
0.06
|
Coronary arteriosclerosis
|
50.6
|
30.8
|
-0.41
|
|
50 - 54
|
1.8
|
2.3
|
0.04
|
Heart disease
|
84.1
|
60.2
|
-0.55
|
|
55 - 59
|
2.6
|
4.4
|
0.10
|
Heart failure
|
44.7
|
25.7
|
-0.41
|
|
60 - 64
|
5.0
|
4.9
|
0.00
|
Ischemic heart disease
|
23.2
|
15.3
|
-0.20
|
|
65 - 69
|
12.9
|
14.3
|
0.04
|
Peripheral vascular disease
|
45.9
|
30.9
|
-0.31
|
|
70 - 74
|
16.5
|
18.5
|
0.05
|
Pulmonary embolism
|
6.8
|
2.5
|
-0.20
|
|
75 - 79
|
15.9
|
14.8
|
-0.03
|
Venous thrombosis
|
12.9
|
6.7
|
-0.21
|
|
80 - 84
|
17.9
|
15.0
|
-0.08
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
13.2
|
10.7
|
-0.08
|
Hematologic neoplasm
|
18.8
|
7.5
|
-0.34
|
|
90 - 94
|
4.1
|
5.0
|
0.04
|
Malignant lymphoma
|
8.8
|
2.8
|
-0.26
|
|
95 - 99
|
3.8
|
3.4
|
-0.02
|
Malignant neoplasm of anorectum
|
5.0
|
2.5
|
-0.13
|
|
100 - 104
|
0.9
|
0.5
|
-0.05
|
Malignant neoplastic disease
|
45.3
|
26.0
|
-0.41
|
|
Gender: female
|
61.8
|
59.8
|
-0.04
|
Malignant tumor of breast
|
8.2
|
3.6
|
-0.20
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
13.2
|
4.9
|
-0.29
|
|
Acute respiratory disease
|
40.0
|
23.6
|
-0.36
|
Malignant tumor of urinary bladder
|
6.2
|
2.5
|
-0.18
|
|
Attention deficit hyperactivity disorder
|
0.3
|
0.3
|
0.00
|
Medication use
|
|
|
|
|
Chronic liver disease
|
6.2
|
2.1
|
-0.21
|
Agents acting on the renin-angiotensin system
|
66.2
|
72.2
|
0.13
|
|
Chronic obstructive lung disease
|
12.4
|
7.8
|
-0.15
|
Antibacterials for systemic use
|
51.5
|
55.5
|
0.08
|
|
Crohn’s disease
|
1.2
|
0.6
|
-0.06
|
Antidepressants
|
64.4
|
61.1
|
-0.07
|
|
Dementia
|
20.6
|
15.9
|
-0.12
|
Antiepileptics
|
36.2
|
36.7
|
0.01
|
|
Depressive disorder
|
18.2
|
11.4
|
-0.19
|
Antiinflammatory and antirheumatic products
|
32.9
|
36.1
|
0.07
|
|
Diabetes mellitus
|
74.4
|
56.4
|
-0.39
|
Antineoplastic agents
|
23.2
|
15.2
|
-0.21
|
|
Gastroesophageal reflux disease
|
27.1
|
16.2
|
-0.27
|
Antipsoriatics
|
1.2
|
1.0
|
-0.02
|
|
Gastrointestinal hemorrhage
|
12.6
|
6.4
|
-0.21
|
Antithrombotic agents
|
62.9
|
52.3
|
-0.22
|
|
Human immunodeficiency virus infection
|
0.3
|
0.7
|
0.06
|
Beta blocking agents
|
61.2
|
63.4
|
0.05
|
|
Hyperlipidemia
|
35.0
|
25.5
|
-0.21
|
Calcium channel blockers
|
49.1
|
56.6
|
0.15
|
|
Hypertensive disorder
|
8.8
|
5.0
|
-0.15
|
Diuretics
|
69.1
|
71.7
|
0.06
|
|
Lesion of liver
|
6.8
|
3.3
|
-0.16
|
Drugs for acid related disorders
|
56.5
|
46.8
|
-0.19
|
|
Obesity
|
12.1
|
6.6
|
-0.19
|
Drugs for obstructive airway diseases
|
46.8
|
35.3
|
-0.23
|
|
Osteoarthritis
|
54.7
|
38.6
|
-0.33
|
Drugs used in diabetes
|
60.3
|
63.9
|
0.07
|
|
Psoriasis
|
2.6
|
1.9
|
-0.05
|
Immunosuppressants
|
7.1
|
5.8
|
-0.05
|
|
Renal impairment
|
39.7
|
25.1
|
-0.32
|
Lipid modifying agents
|
67.9
|
74.1
|
0.14
|
|
Rheumatoid arthritis
|
8.8
|
7.5
|
-0.05
|
Opioids
|
42.1
|
35.3
|
-0.14
|
|
Schizophrenia
|
11.5
|
6.6
|
-0.17
|
Psycholeptics
|
61.2
|
53.7
|
-0.15
|
|
Ulcerative colitis
|
0.6
|
0.2
|
-0.06
|
Psychostimulants, agents used for adhd and nootropics
|
13.5
|
15.4
|
0.05
|
|
Urinary tract infectious disease
|
36.2
|
24.0
|
-0.27
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
3.1
|
1.0
|
-0.15
|
|
25 - 29
|
0.5
|
0.5
|
0.00
|
Visual system disorder
|
49.7
|
36.3
|
-0.27
|
|
30 - 34
|
0.2
|
0.6
|
0.06
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
1.0
|
0.00
|
Atrial fibrillation
|
43.2
|
27.2
|
-0.34
|
|
40 - 44
|
1.2
|
1.1
|
-0.01
|
Cerebrovascular disease
|
14.8
|
9.9
|
-0.15
|
|
45 - 49
|
2.8
|
1.4
|
-0.10
|
Coronary arteriosclerosis
|
47.0
|
30.6
|
-0.34
|
|
50 - 54
|
1.8
|
2.3
|
0.04
|
Heart disease
|
82.9
|
56.5
|
-0.60
|
|
55 - 59
|
3.9
|
2.9
|
-0.06
|
Heart failure
|
40.1
|
23.4
|
-0.36
|
|
60 - 64
|
2.9
|
3.3
|
0.02
|
Ischemic heart disease
|
27.1
|
15.2
|
-0.29
|
|
65 - 69
|
14.6
|
16.2
|
0.04
|
Peripheral vascular disease
|
42.1
|
27.6
|
-0.31
|
|
70 - 74
|
21.5
|
21.4
|
0.00
|
Pulmonary embolism
|
4.1
|
2.5
|
-0.09
|
|
75 - 79
|
14.8
|
17.2
|
0.07
|
Venous thrombosis
|
10.9
|
6.9
|
-0.14
|
|
80 - 84
|
15.8
|
15.4
|
-0.01
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.7
|
9.4
|
-0.07
|
Hematologic neoplasm
|
15.3
|
7.8
|
-0.24
|
|
90 - 94
|
4.3
|
4.0
|
-0.02
|
Malignant lymphoma
|
7.8
|
3.9
|
-0.17
|
|
95 - 99
|
2.3
|
2.5
|
0.01
|
Malignant neoplasm of anorectum
|
3.6
|
1.2
|
-0.16
|
|
100 - 104
|
0.7
|
0.8
|
0.01
|
Malignant neoplastic disease
|
42.2
|
25.8
|
-0.35
|
|
Gender: female
|
55.9
|
54.0
|
-0.04
|
Malignant tumor of breast
|
6.3
|
4.1
|
-0.10
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
7.5
|
3.4
|
-0.18
|
|
Acute respiratory disease
|
35.6
|
19.5
|
-0.37
|
Malignant tumor of urinary bladder
|
5.1
|
2.8
|
-0.12
|
|
Attention deficit hyperactivity disorder
|
0.6
|
0.3
|
-0.04
|
Medication use
|
|
|
|
|
Chronic liver disease
|
5.7
|
2.0
|
-0.19
|
Agents acting on the renin-angiotensin system
|
41.6
|
0
|
-1.19
|
|
Chronic obstructive lung disease
|
13.4
|
5.3
|
-0.28
|
Antibacterials for systemic use
|
39.4
|
0
|
-1.14
|
|
Crohn’s disease
|
0.7
|
0.6
|
-0.01
|
Antidepressants
|
38.2
|
0
|
-1.11
|
|
Dementia
|
20.8
|
12.5
|
-0.22
|
Antiepileptics
|
23.9
|
0
|
-0.79
|
|
Depressive disorder
|
9.6
|
8.4
|
-0.04
|
Antiinflammatory and antirheumatic products
|
23.8
|
0
|
-0.79
|
|
Diabetes mellitus
|
68.9
|
49.3
|
-0.41
|
Antineoplastic agents
|
14.5
|
0
|
-0.58
|
|
Gastroesophageal reflux disease
|
21.6
|
14.5
|
-0.19
|
Antipsoriatics
|
0.1
|
0
|
-0.04
|
|
Gastrointestinal hemorrhage
|
9.8
|
5.5
|
-0.16
|
Antithrombotic agents
|
39.3
|
0
|
-1.14
|
|
Human immunodeficiency virus infection
|
0.6
|
0.2
|
-0.06
|
Beta blocking agents
|
39.2
|
0
|
-1.14
|
|
Hyperlipidemia
|
35.9
|
26.7
|
-0.20
|
Calcium channel blockers
|
29.9
|
0
|
-0.92
|
|
Hypertensive disorder
|
6.6
|
3.1
|
-0.16
|
Diuretics
|
43.6
|
0
|
-1.24
|
|
Lesion of liver
|
6.8
|
3.2
|
-0.17
|
Drugs for acid related disorders
|
30.1
|
0
|
-0.93
|
|
Obesity
|
8.6
|
4.7
|
-0.16
|
Drugs for obstructive airway diseases
|
27.1
|
0
|
-0.86
|
|
Osteoarthritis
|
53.0
|
39.6
|
-0.27
|
Drugs used in diabetes
|
34.6
|
0
|
-1.03
|
|
Psoriasis
|
1.5
|
1.6
|
0.01
|
Immunosuppressants
|
4.3
|
0
|
-0.30
|
|
Renal impairment
|
36.7
|
21.1
|
-0.35
|
Lipid modifying agents
|
44.8
|
0
|
-1.27
|
|
Rheumatoid arthritis
|
10.5
|
5.2
|
-0.20
|
Opioids
|
27.2
|
0
|
-0.86
|
|
Schizophrenia
|
7.3
|
3.2
|
-0.18
|
Psycholeptics
|
40.1
|
0
|
-1.16
|
|
Ulcerative colitis
|
0.5
|
0.2
|
-0.05
|
Psychostimulants, agents used for adhd and nootropics
|
10.8
|
0
|
-0.49
|
|
Urinary tract infectious disease
|
31.2
|
19.1
|
-0.28
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
3.1
|
1.0
|
-0.15
|
|
25 - 29
|
0.5
|
0.5
|
0.00
|
Visual system disorder
|
49.7
|
36.3
|
-0.27
|
|
30 - 34
|
0.2
|
0.6
|
0.06
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
1.0
|
0.00
|
Atrial fibrillation
|
43.2
|
27.2
|
-0.34
|
|
40 - 44
|
1.2
|
1.1
|
-0.01
|
Cerebrovascular disease
|
14.8
|
9.9
|
-0.15
|
|
45 - 49
|
2.8
|
1.4
|
-0.10
|
Coronary arteriosclerosis
|
47.0
|
30.6
|
-0.34
|
|
50 - 54
|
1.8
|
2.3
|
0.04
|
Heart disease
|
82.9
|
56.5
|
-0.60
|
|
55 - 59
|
3.9
|
2.9
|
-0.06
|
Heart failure
|
40.1
|
23.4
|
-0.36
|
|
60 - 64
|
2.9
|
3.3
|
0.02
|
Ischemic heart disease
|
27.1
|
15.2
|
-0.29
|
|
65 - 69
|
14.6
|
16.2
|
0.04
|
Peripheral vascular disease
|
42.1
|
27.6
|
-0.31
|
|
70 - 74
|
21.5
|
21.4
|
0.00
|
Pulmonary embolism
|
4.1
|
2.5
|
-0.09
|
|
75 - 79
|
14.8
|
17.2
|
0.07
|
Venous thrombosis
|
10.9
|
6.9
|
-0.14
|
|
80 - 84
|
15.8
|
15.4
|
-0.01
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.7
|
9.4
|
-0.07
|
Hematologic neoplasm
|
15.3
|
7.8
|
-0.24
|
|
90 - 94
|
4.3
|
4.0
|
-0.02
|
Malignant lymphoma
|
7.8
|
3.9
|
-0.17
|
|
95 - 99
|
2.3
|
2.5
|
0.01
|
Malignant neoplasm of anorectum
|
3.6
|
1.2
|
-0.16
|
|
100 - 104
|
0.7
|
0.8
|
0.01
|
Malignant neoplastic disease
|
42.2
|
25.8
|
-0.35
|
|
Gender: female
|
55.9
|
54.0
|
-0.04
|
Malignant tumor of breast
|
6.3
|
4.1
|
-0.10
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
7.5
|
3.4
|
-0.18
|
|
Acute respiratory disease
|
35.6
|
19.5
|
-0.37
|
Malignant tumor of urinary bladder
|
5.1
|
2.8
|
-0.12
|
|
Attention deficit hyperactivity disorder
|
0.6
|
0.3
|
-0.04
|
Medication use
|
|
|
|
|
Chronic liver disease
|
5.7
|
2.0
|
-0.19
|
Agents acting on the renin-angiotensin system
|
41.6
|
0
|
-1.19
|
|
Chronic obstructive lung disease
|
13.4
|
5.3
|
-0.28
|
Antibacterials for systemic use
|
39.4
|
0
|
-1.14
|
|
Crohn’s disease
|
0.7
|
0.6
|
-0.01
|
Antidepressants
|
38.2
|
0
|
-1.11
|
|
Dementia
|
20.8
|
12.5
|
-0.22
|
Antiepileptics
|
23.9
|
0
|
-0.79
|
|
Depressive disorder
|
9.6
|
8.4
|
-0.04
|
Antiinflammatory and antirheumatic products
|
23.8
|
0
|
-0.79
|
|
Diabetes mellitus
|
68.9
|
49.3
|
-0.41
|
Antineoplastic agents
|
14.5
|
0
|
-0.58
|
|
Gastroesophageal reflux disease
|
21.6
|
14.5
|
-0.19
|
Antipsoriatics
|
0.1
|
0
|
-0.04
|
|
Gastrointestinal hemorrhage
|
9.8
|
5.5
|
-0.16
|
Antithrombotic agents
|
39.3
|
0
|
-1.14
|
|
Human immunodeficiency virus infection
|
0.6
|
0.2
|
-0.06
|
Beta blocking agents
|
39.2
|
0
|
-1.14
|
|
Hyperlipidemia
|
35.9
|
26.7
|
-0.20
|
Calcium channel blockers
|
29.9
|
0
|
-0.92
|
|
Hypertensive disorder
|
6.6
|
3.1
|
-0.16
|
Diuretics
|
43.6
|
0
|
-1.24
|
|
Lesion of liver
|
6.8
|
3.2
|
-0.17
|
Drugs for acid related disorders
|
30.1
|
0
|
-0.93
|
|
Obesity
|
8.6
|
4.7
|
-0.16
|
Drugs for obstructive airway diseases
|
27.1
|
0
|
-0.86
|
|
Osteoarthritis
|
53.0
|
39.6
|
-0.27
|
Drugs used in diabetes
|
34.6
|
0
|
-1.03
|
|
Psoriasis
|
1.5
|
1.6
|
0.01
|
Immunosuppressants
|
4.3
|
0
|
-0.30
|
|
Renal impairment
|
36.7
|
21.1
|
-0.35
|
Lipid modifying agents
|
44.8
|
0
|
-1.27
|
|
Rheumatoid arthritis
|
10.5
|
5.2
|
-0.20
|
Opioids
|
27.2
|
0
|
-0.86
|
|
Schizophrenia
|
7.3
|
3.2
|
-0.18
|
Psycholeptics
|
40.1
|
0
|
-1.16
|
|
Ulcerative colitis
|
0.5
|
0.2
|
-0.05
|
Psychostimulants, agents used for adhd and nootropics
|
10.8
|
0
|
-0.49
|
|
Urinary tract infectious disease
|
31.2
|
19.1
|
-0.28
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
antithrombotic agents
|
428
|
|
beta blocking agents
|
416
|
|
alimentary tract and metabolism
|
310
|
|
nervous system
|
305
|
|
cardiovascular system
|
300
|
|
blood and blood forming organs
|
275
|
|
all other therapeutic products
|
266
|
|
respiratory system
|
260
|
|
antiepileptics
|
246
|
|
analgesics
|
244
|
|
ophthalmologicals
|
244
|
|
sensory organs
|
244
|
|
antihistamines for systemic use
|
238
|
|
diuretics
|
235
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
234
|
|
psychoanaleptics
|
233
|
|
lipid modifying agents
|
231
|
|
lipid modifying agents, plain
|
231
|
|
agents acting on the renin-angiotensin system
|
225
|
|
antidepressants
|
219
|
|
hmg coa reductase inhibitors
|
210
|
|
psycholeptics
|
208
|
|
drugs used in diabetes
|
205
|
|
blood glucose lowering drugs, excl. insulins
|
201
|
|
stomatological preparations
|
200
|
|
cond_180_days
|
n_180_days
|
|
heart disease
|
286
|
|
pain
|
282
|
|
inflammation of specific body systems
|
279
|
|
pain finding at anatomical site
|
277
|
|
arthropathy
|
273
|
|
inflammation of specific body organs
|
267
|
|
measurement finding outside reference range
|
265
|
|
vascular disorder
|
258
|
|
diabetes mellitus
|
253
|
|
soft tissue lesion
|
240
|
|
type 2 diabetes mellitus
|
234
|
|
pain of truncal structure
|
222
|
|
abnormal blood cell count
|
212
|
|
neoplastic disease
|
212
|
|
measurement finding below reference range
|
208
|
|
structural disorder of heart
|
207
|
|
cardiac arrhythmia
|
204
|
|
arteriosclerotic vascular disease
|
199
|
|
cytopenia
|
199
|
|
erythropenia
|
199
|
|
rbc count abnormal
|
199
|
|
rbc count low
|
199
|
|
hemoglobin level outside reference range
|
198
|
|
hemoglobin low
|
198
|
|
anemia
|
197
|